{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T08:58:44Z","timestamp":1775984324943,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T00:00:00Z","timestamp":1439942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T00:00:00Z","timestamp":1439942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Enfuvirtide (T20), is the first HIV fusion inhibitor approved for treatment of HIV\/AIDS patients who fail to respond to the current antiretroviral drugs. However, its clinical application is limited because of short half-life, drug resistance and cross-reactivity with the preexisting antibodies in HIV-infected patients. Using an artificial peptide strategy, we designed a peptide with non-native protein sequence, AP3, which exhibited potent antiviral activity against a broad spectrum of HIV-1 strains, including those resistant to T20 and had remarkably longer <jats:italic>in vivo<\/jats:italic> half-life than T20. While the preexisting antibodies in HIV-infected patients significantly suppressed T20\u2019s antiviral activity, these antibodies neither recognized AP3, nor attenuated its anti-HIV-1 activity. Structurally different from T20, AP3 could fold into single-helix and interact with gp41 NHR. The two residues, Met and Thr, at the N-terminus of AP3 form a hook-like structure to stabilize interaction between AP3 and NHR helices. Therefore, AP3 has potential for further development as a new HIV fusion inhibitor with improved antiviral efficacy, resistance profile and pharmacological properties over enfuvirtide. Meanwhile, this study highlighted the advantages of artificially designed peptides and confirmed that this strategy could be used in developing artificial peptide-based viral fusion inhibitors against HIV and other enveloped viruses.<\/jats:p>","DOI":"10.1038\/srep13028","type":"journal-article","created":{"date-parts":[[2015,8,19]],"date-time":"2015-08-19T10:00:51Z","timestamp":1439978451000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy"],"prefix":"10.1038","volume":"5","author":[{"given":"Xiaojie","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanying","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongguang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,19]]},"reference":[{"key":"BFsrep13028_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0092-8674(00)81430-0","volume":"93","author":"DC Chan","year":"1998","unstructured":"Chan, D. C. & Kim, P. S. HIV Entry and Its Inhibition. Cell 93, 681\u2013684 (1998).","journal-title":"Cell"},{"key":"BFsrep13028_CR2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/nsb1295-1075","volume":"2","author":"M Lu","year":"1995","unstructured":"Lu, M., Blacklow, S. C. & Kim, P. S. A Trimeric Structural Domain of the HIV-1 Transmembrane Glycoprotein. Nat. Struct. Biol. 2, 1075\u20131082 (1995).","journal-title":"Nat. Struct. Biol"},{"key":"BFsrep13028_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","volume":"89","author":"DC Chan","year":"1997","unstructured":"Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core Structure of Gp41 From the HIV Envelope Glycoprotein. Cell 89, 263\u2013273 (1997).","journal-title":"Cell"},{"key":"BFsrep13028_CR4","doi-asserted-by":"publisher","first-page":"12303","DOI":"10.1073\/pnas.94.23.12303","volume":"94","author":"K Tan","year":"1997","unstructured":"Tan, K. et al. Atomic Structure of a Thermostable Subdomain of HIV-1 Gp41. Proc. Natl. Acad. Sci. USA 94, 12303\u201312308 (1997).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep13028_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/387426a0","volume":"387","author":"W Weissenhorn","year":"1997","unstructured":"Weissenhorn, W. et al. Atomic Structure of the Ectodomain From HIV-1 Gp41. Nature 387, 426\u2013428 (1997).","journal-title":"Nature"},{"key":"BFsrep13028_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/365113a0","volume":"365","author":"S Jiang","year":"1993","unstructured":"Jiang, S., Lin, K., Strick, N. & Neurath, A. R. HIV-1 Inhibition by a Peptide. Nature 365, 113 (1993).","journal-title":"Nature"},{"key":"BFsrep13028_CR7","doi-asserted-by":"publisher","first-page":"9770","DOI":"10.1073\/pnas.91.21.9770","volume":"91","author":"CT Wild","year":"1994","unstructured":"Wild, C. T. et al. Peptides Corresponding to a Predictive Alpha-Helical Domain of Human Immunodeficiency Virus Type 1 Gp41 Are Potent Inhibitors of Virus Infection . Proc. Natl. Acad. Sci. USA 91, 9770\u20139774 (1994).","journal-title":". Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep13028_CR8","doi-asserted-by":"publisher","first-page":"11259","DOI":"10.1074\/jbc.M411141200","volume":"280","author":"S Liu","year":"2005","unstructured":"Liu, S. et al. Different From the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in Gp41 and Gp120. J. Biol. Chem. 280, 11259\u201311273 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFsrep13028_CR9","doi-asserted-by":"publisher","first-page":"9612","DOI":"10.1074\/jbc.M609148200","volume":"282","author":"S Liu","year":"2007","unstructured":"Liu, S. et al. HIV Gp41 C-Terminal Heptad Repeat Contains Multifunctional Domains: Relation to Mechanisms of Action of Anti-HIV Peptides. J. Biol. Chem. 282, 9612\u20139620 (2007).","journal-title":"J. Biol. Chem."},{"key":"BFsrep13028_CR10","doi-asserted-by":"publisher","first-page":"12447","DOI":"10.1128\/JVI.79.19.12447-12454.2005","volume":"79","author":"M Mink","year":"2005","unstructured":"Mink, M. et al. Impact of Human Immunodeficiency Virus Type 1 Gp41 Amino Acid Substitutions Selected During Enfuvirtide Treatment on Gp41 Binding and Antiviral Potency of Enfuvirtide in Vitro. J. Virol. 79, 12447\u201312454 (2005).","journal-title":"J. Virol."},{"key":"BFsrep13028_CR11","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/01.qai.0000234083.34161.55","volume":"43","author":"J Lu","year":"2006","unstructured":"Lu, J. et al. Rapid Emergence of Enfuvirtide Resistance in HIV-1-Infected Patients: Results of a Clonal Analysis. J. Acquir. Immune. Defic. Syndr. 43, 60\u201364 (2006).","journal-title":"J. Acquir. Immune. Defic. Syndr."},{"key":"BFsrep13028_CR12","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1097\/00002030-200409030-00007","volume":"18","author":"PR Sista","year":"2004","unstructured":"Sista, P. R. et al. Characterization of Determinants of Genotypic and Phenotypic Resistance to Enfuvirtide in Baseline and on-Treatment HIV-1 Isolates. AIDS 18, 1787\u20131794 (2004).","journal-title":"AIDS"},{"key":"BFsrep13028_CR13","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/JVI.72.2.986-993.1998","volume":"72","author":"LT Rimsky","year":"1998","unstructured":"Rimsky, L. T., Shugars, D. C. & Matthews, T. J. Determinants of Human Immunodeficiency Virus Type 1 Resistance to Gp41-Derived Inhibitory Peptides. J. Virol. 72, 986\u2013993 (1998).","journal-title":"J. Virol."},{"key":"BFsrep13028_CR14","first-page":"254","volume":"38","author":"N Vincent","year":"2005","unstructured":"Vincent, N. et al. Depletion in Antibodies Targeted to the HR2 Region of HIV-1 Glycoprotein Gp41 in Sera of HIV-1-Seropositive Patients Treated With T20. J Acquir. Immune. Defic. Syndr. 38, 254\u2013262 (2005).","journal-title":"J Acquir. Immune. Defic. Syndr."},{"key":"BFsrep13028_CR15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.imbio.2012.01.007","volume":"217","author":"N Vincent","year":"2012","unstructured":"Vincent, N. & Malvoisin, E. Ability of Antibodies Specific to the HIV-1 Envelope Glycoprotein to Block the Fusion Inhibitor T20 in a Cell-Cell Fusion Assay. Immunobiology 217, 943\u2013950 (2012).","journal-title":"Immunobiology"},{"key":"BFsrep13028_CR16","doi-asserted-by":"publisher","first-page":"11579","DOI":"10.1039\/c2cc35973a","volume":"48","author":"W Shi","year":"2012","unstructured":"Shi, W. et al. Design of Highly Potent HIV Fusion Inhibitors Based on Artificial Peptide Sequences. Chem. Commun. (Camb.) 48, 11579\u201311581 (2012).","journal-title":"Chem. Commun. (Camb.)"},{"key":"BFsrep13028_CR17","doi-asserted-by":"publisher","first-page":"34558","DOI":"10.1074\/jbc.M112.390393","volume":"287","author":"H Chong","year":"2012","unstructured":"Chong, H. et al. The M-T Hook Structure Is Critical for Design of HIV-1 Fusion Inhibitors. J Biol Chem 287, 34558\u201334568 (2012).","journal-title":"J Biol Chem"},{"key":"BFsrep13028_CR18","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/jac\/dku183","volume":"69","author":"H Chong","year":"2014","unstructured":"Chong, H. et al. The M-T Hook Structure Increases the Potency of HIV-1 Fusion Inhibitor Sifuvirtide and Overcomes Drug Resistance. J. Antimicrob. Chemother. 69, 2759\u20132769 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep13028_CR19","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","volume":"363","author":"S Liu","year":"2004","unstructured":"Liu, S. et al. Interaction Between Heptad Repeat 1 and 2 Regions in Spike Protein of SARS-Associated Coronavirus: Implications for Virus Fusogenic Mechanism and Identification of Fusion Inhibitors. Lancet 363, 938\u2013947 (2004).","journal-title":"Lancet"},{"key":"BFsrep13028_CR20","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1038\/ncomms4067","volume":"5","author":"L Lu","year":"2014","unstructured":"Lu, L. et al. Structure-Based Discovery of Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor. Nat. Commun. 5, 3067 (2014).","journal-title":"Nat. Commun."},{"key":"BFsrep13028_CR21","doi-asserted-by":"publisher","first-page":"E2596","DOI":"10.1073\/pnas.1408983111","volume":"111","author":"TA Poor","year":"2014","unstructured":"Poor, T. A. et al. Probing the Paramyxovirus Fusion (F) Protein-Refolding Event From Pre- to Postfusion by Oxidative Footprinting. Proc. Natl. Acad. Sci. USA 111, E2596\u2013E2605 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep13028_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1089\/088922202760072294","volume":"18","author":"JM Kilby","year":"2002","unstructured":"Kilby, J. M. et al. The Safety, Plasma Pharmacokinetics and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of Gp41-Mediated Virus Fusion, in HIV-Infected Adults. AIDS Res. Hum. Retroviruses 18, 685\u2013693 (2002).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"BFsrep13028_CR23","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMoa035026","volume":"348","author":"JP Lalezari","year":"2003","unstructured":"Lalezari, J. P. et al. Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America. N. Engl. J. Med. 348, 2175\u20132185 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep13028_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1128\/AAC.50.2.667-673.2006","volume":"50","author":"H Stocker","year":"2006","unstructured":"Stocker, H. et al. Pharmacokinetics of Enfuvirtide in Patients Treated in Typical Routine Clinical Settings. Antimicrob. Agents Chemother. 50, 667\u2013673 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep13028_CR25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/135965350601100714","volume":"11","author":"SA Myers","year":"2006","unstructured":"Myers, S. A. et al. A Prospective Clinical and Pathological Examination of Injection Site Reactions With the HIV-1 Fusion Inhibitor Enfuvirtide. Antivir. Ther. 11, 935\u2013939 (2006).","journal-title":"Antivir. Ther."},{"key":"BFsrep13028_CR26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1093\/jac\/dkh141","volume":"53","author":"P Maggi","year":"2004","unstructured":"Maggi, P. et al. Cutaneous Injection Site Reactions to Long-Term Therapy With Enfuvirtide. J. Antimicrob. Chemother. 53, 678\u2013681 (2004).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep13028_CR27","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/j.peptides.2003.07.013","volume":"24","author":"S Liu","year":"2003","unstructured":"Liu, S., Zhao, Q. & Jiang, S. Determination of the HIV-1 Gp41 Postfusion Conformation Modeled by Synthetic Peptides: Applicable for Identification of the HIV-1 Fusion Inhibitors. Peptide 24, 1303\u20131313 (2003).","journal-title":"Peptide"},{"key":"BFsrep13028_CR28","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.1128\/AAC.00670-09","volume":"53","author":"H Wang","year":"2009","unstructured":"Wang, H. et al. ADS-J1 Inhibits HIV-1 Entry by Interacting With the Gp41 Pocket Region and Blocking the Fusion-Active Gp41 Core Formation. Antimicrob. Agents Chemother. 53, 4987\u20134998 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep13028_CR29","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.bbamem.2013.12.022","volume":"1838","author":"F Yu","year":"2014","unstructured":"Yu, F. et al. ADS-J1 Inhibits HIV-1 Infection and Membrane Fusion by Targeting the Highly Conserved Pocket in the Gp41 NHR-Trimer. Biochim. Biophys Acta 1838, 1296\u20131305 (2014).","journal-title":"Biochim. Biophys Acta"},{"key":"BFsrep13028_CR30","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1002\/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J","volume":"41","author":"A Otaka","year":"2002","unstructured":"Otaka, A. et al. Remodeling of Gp41-C34 Peptide Leads to Highly Effective Inhibitors of the Fusion of HIV-1 With Target Cells. Angew. Chem. Int. Ed Engl. 41, 2937\u20132940 (2002).","journal-title":"Angew. Chem. Int. Ed Engl."},{"key":"BFsrep13028_CR31","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1056\/NEJMoa035211","volume":"348","author":"A Lazzarin","year":"2003","unstructured":"Lazzarin, A. et al. Efficacy of Enfuvirtide in Patients Infected With Drug-Resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348, 2186\u20132195 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFsrep13028_CR32","unstructured":"FDA approved FUZEON (enfuvirtide, also known as T-20). &lt; http:\/\/www.fda.gov\/ForPatients\/Illness\/HIVAIDS\/History\/ucm151081.htm#2003&gt;. (2003) Date of access: 06\/06\/2015."},{"key":"BFsrep13028_CR33","doi-asserted-by":"publisher","first-page":"12772","DOI":"10.1073\/pnas.0701478104","volume":"104","author":"JJ Dwyer","year":"2007","unstructured":"Dwyer, J. J. et al. Design of Helical, Oligomeric HIV-1 Fusion Inhibitor Peptides With Potent Activity Against Enfuvirtide-Resistant Virus. Proc. Natl. Acad. Sci. USA 104, 12772\u201312777 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep13028_CR34","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1128\/AAC.46.6.1896-1905.2002","volume":"46","author":"X Wei","year":"2002","unstructured":"Wei, X. et al. Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy. Antimicrob. Agents Chemother. 46, 1896\u20131905 (2002).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep13028_CR35","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/3293","volume":"4","author":"JM Kilby","year":"1998","unstructured":"Kilby, J. M. et al. Potent Suppression of HIV-1 Replication in Humans by T-20, a Peptide Inhibitor of Gp41-Mediated Virus Entry. Nature Med. 4, 1302\u20131307 (1998).","journal-title":"Nature Med."},{"key":"BFsrep13028_CR36","doi-asserted-by":"publisher","first-page":"12428","DOI":"10.1128\/JVI.78.22.12428-12437.2004","volume":"78","author":"CE Baldwin","year":"2004","unstructured":"Baldwin, C. E. et al. Emergence of a Drug-Dependent Human Immunodeficiency Virus Type 1 Variant During Therapy With the T20 Fusion Inhibitor. J. Virol. 78, 12428\u201312437 (2004).","journal-title":"J. Virol."},{"key":"BFsrep13028_CR37","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1128\/JVI.02496-08","volume":"83","author":"N Ray","year":"2009","unstructured":"Ray, N., Blackburn, L. A. & Doms, R. W. HR-2 Mutations in Human Immunodeficiency Virus Type 1 Gp41 Restore Fusion Kinetics Delayed by HR-1 Mutations That Cause Clinical Resistance to Enfuvirtide. J. Virol. 83, 2989\u20132995 (2009).","journal-title":"J. Virol."},{"key":"BFsrep13028_CR38","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1128\/AAC.49.3.1113-1119.2005","volume":"49","author":"L Xu","year":"2005","unstructured":"Xu, L. et al. Emergence and Evolution of Enfuvirtide Resistance Following Long-Term Therapy Involves Heptad Repeat 2 Mutations Within Gp41. Antimicrob. Agents Chemother. 49, 1113\u20131119 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFsrep13028_CR39","doi-asserted-by":"publisher","first-page":"15613","DOI":"10.1073\/pnas.95.26.15613","volume":"95","author":"DC Chan","year":"1998","unstructured":"Chan, D. C., Chutkowski, C. T. & Kim, P. S. Evidence That a Prominent Cavity in the Coiled Coil of HIV Type 1 Gp41 Is an Attractive Drug Target. Proc. Natl. Acad. Sci. USA 95, 15613\u201315617 (1998).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep13028_CR40","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1128\/JVI.73.10.8578-8586.1999","volume":"73","author":"H Ji","year":"1999","unstructured":"Ji, H. et al. Inhibition of HIV-1 Infectivity by the Gp41 Core: Role of a Conserved Hydrophobic Cavity in Membrane Fusion. J. Virol. 73, 8578\u20138586 (1999).","journal-title":"J. Virol."},{"key":"BFsrep13028_CR41","doi-asserted-by":"publisher","first-page":"6678","DOI":"10.1128\/JVI.00352-08","volume":"82","author":"D Eggink","year":"2008","unstructured":"Eggink, D. et al. Selection of T1249-Resistant Human Immunodeficiency Virus Type 1 Variants. J. Virol. 82, 6678\u20136688 (2008).","journal-title":"J. Virol."},{"key":"BFsrep13028_CR42","unstructured":"Eron, J., Merigan, T., Kibly, M., Yangco, B., Gleavy, J., Rusnak, P., DiMassimo, B., Smith, R., Baker, B., Duff, F., Drucker, J., Matthews, T. & Hopkins, S. ; for the T-1249-101 Study Group. A 14-day assayment of the safety, pharmacokinetics and antiviral activity of T-1249, a peptide inhibitor of membrane fusion (Abstract 14). Programs and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections.February 4-8, 2001 . 2001. Chicago, IL."},{"key":"BFsrep13028_CR43","first-page":"95","volume":"15","author":"J Feinberg","year":"2003","unstructured":"Feinberg, J. Meeting Notes From the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). T-1249 for T-20 Salvage. AIDS Clin. Care 15, 95\u201396 (2003).","journal-title":"AIDS Clin. Care"},{"key":"BFsrep13028_CR44","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1128\/JVI.00319-08","volume":"82","author":"Y He","year":"2008","unstructured":"He, Y. et al. Identification of a Critical Motif for the HIV-1 Gp41 Core Structure: Implication for Designing Novel Anti-HIV Fusion Inhibitors. J. Virol. 82, 6349\u20136358 (2008).","journal-title":"J. Virol."},{"key":"BFsrep13028_CR45","doi-asserted-by":"publisher","first-page":"11126","DOI":"10.1074\/jbc.M800200200","volume":"283","author":"Y He","year":"2008","unstructured":"He, Y. et al. Design and Evaluation of Sifuvirtide, a Novel HIV-1 Fusion Inhibitor. J. Biol. Chem. 283, 11126\u201311134 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFsrep13028_CR46","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1128\/JVI.00791-15","volume":"89","author":"Q Wang","year":"2015","unstructured":"Wang, Q. et al. Non-Neutralizing Antibodies Induced by HIV-1 Gp41 NHR Domain Gain Neutralizing Activity in the Presence of HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy. J. Virol. 89, 6960\u20136964 (2015).","journal-title":"J. Virol."},{"key":"BFsrep13028_CR47","doi-asserted-by":"publisher","first-page":"9184","DOI":"10.1016\/j.bmc.2008.09.018","volume":"16","author":"H Nishikawa","year":"2008","unstructured":"Nishikawa, H. et al. Identification of Minimal Sequence for HIV-1 Fusion Inhibitors. Bioorg. Med Chem. 16, 9184\u20139187 (2008).","journal-title":"Bioorg. Med Chem."},{"key":"BFsrep13028_CR48","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1021\/jm701109d","volume":"51","author":"S Oishi","year":"2008","unstructured":"Oishi, S. et al. Design of a Novel HIV-1 Fusion Inhibitor That Displays a Minimal Interface for Binding Affinity. J. Med. Chem. 51, 388\u2013391 (2008).","journal-title":"J. Med. Chem."},{"key":"BFsrep13028_CR49","doi-asserted-by":"publisher","first-page":"E2596","DOI":"10.1073\/pnas.1408983111","volume":"111","author":"TA Poor","year":"2014","unstructured":"Poor, T. A. et al. Probing the Paramyxovirus Fusion (F) Protein-Refolding Event From Pre- to Postfusion by Oxidative Footprinting. Proc. Natl. Acad. Sci. USA 111, E2596\u2013E2605 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep13028_CR50","doi-asserted-by":"publisher","first-page":"16332","DOI":"10.1073\/pnas.0807335105","volume":"105","author":"Y He","year":"2008","unstructured":"He, Y. et al. Potent HIV Fusion Inhibitors Against Enfuvirtide-Resistant HIV-1 Strains. Proc. Natl. Acad. Sci. USA 105, 16332\u201316337 (2008).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"BFsrep13028_CR51","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. Processing of X-Ray Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 276, 307\u2013326 (1997).","journal-title":"Methods Enzymol."},{"key":"BFsrep13028_CR52","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser Crystallographic Software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr"},{"key":"BFsrep13028_CR53","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P., Cowtan, K. Coot: Model-Building Tools for Molecular Graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr"},{"key":"BFsrep13028_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a Comprehensive Python-Based System for Macromolecular Structure Solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr"},{"key":"BFsrep13028_CR55","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1093\/jac\/dkt230","volume":"68","author":"P Tong","year":"2013","unstructured":"Tong, P. et al. An Engineered HIV-1 Gp41 Trimeric Coiled Coil With Increased Stability and Anti-HIV-1 Activity: Implication for Developing Anti-HIV Microbicides. J. Antimicrob. Chemother. 68, 2533\u20132544 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFsrep13028_CR56","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/1742-4690-9-104","volume":"9","author":"L Lu","year":"2012","unstructured":"Lu, L. et al. A Bivalent Recombinant Protein Inactivates HIV-1 by Targeting the Gp41 Prehairpin Fusion Intermediate Induced by CD4 D1D2 Domains. Retrovirology 9, 104 (2012).","journal-title":"Retrovirology"},{"key":"BFsrep13028_CR57","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1016\/j.bbamem.2012.07.020","volume":"1818","author":"L Lu","year":"2012","unstructured":"Lu, L. et al. HIV-1 Variants With a Single-Point Mutation in the Gp41 Pocket Region Exhibiting Different Susceptibility to HIV Fusion Inhibitors With Pocket- or Membrane-Binding Domain. Biochim. Biophys. Acta 1818, 2950\u20132957 (2012).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFsrep13028_CR58","doi-asserted-by":"crossref","first-page":"10213","DOI":"10.1128\/JVI.72.12.10213-10217.1998","volume":"72","author":"S Jiang","year":"1998","unstructured":"Jiang, S., Lin, K. & Lu, M. A Conformation-Specific Monoclonal Antibody Reacting With Fusion-Active Gp41 From the HIV-1 Envelope Glycoprotein. J. Virol. 72, 10213\u201310217 (1998).","journal-title":"J. Virol."},{"key":"BFsrep13028_CR59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0166-0934(99)00041-5","volume":"80","author":"S Jiang","year":"1999","unstructured":"Jiang, S., Lin, K., Zhang, L. & Debnath, A. K. A Screening Assay for Antiviral Compounds Targeted to the HIV-1 Gp41 Core Structure Using a Conformation-Specific Monoclonal Antibody. J. Virol. Methods 80, 85\u201396 (1999).","journal-title":"J. Virol. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep13028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep13028","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep13028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T23:45:10Z","timestamp":1672962310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep13028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,19]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,10,16]]}},"alternative-id":["BFsrep13028"],"URL":"https:\/\/doi.org\/10.1038\/srep13028","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,19]]},"assertion":[{"value":"24 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13028"}}